253 related articles for article (PubMed ID: 19416910)
1. Genetic dissection of histone deacetylase requirement in tumor cells.
Haberland M; Johnson A; Mokalled MH; Montgomery RL; Olson EN
Proc Natl Acad Sci U S A; 2009 May; 106(19):7751-5. PubMed ID: 19416910
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
3. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors: Potential in cancer therapy.
Marks PA; Xu WS
J Cell Biochem; 2009 Jul; 107(4):600-8. PubMed ID: 19459166
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
6. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
8. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
10. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
12. Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Schäfer C; Göder A; Beyer M; Kiweler N; Mahendrarajah N; Rauch A; Nikolova T; Stojanovic N; Wieczorek M; Reich TR; Tomicic MT; Linnebacher M; Sonnemann J; Dietrich S; Sellmer A; Mahboobi S; Heinzel T; Schneider G; Krämer OH
Cell Signal; 2017 Jan; 29():218-225. PubMed ID: 27838375
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
Lee AY; Paweletz CP; Pollock RM; Settlage RE; Cruz JC; Secrist JP; Miller TA; Stanton MG; Kral AM; Ozerova ND; Meng F; Yates NA; Richon V; Hendrickson RC
J Proteome Res; 2008 Dec; 7(12):5177-86. PubMed ID: 19367703
[TBL] [Abstract][Full Text] [Related]
14. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
16. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
17. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
18. Functional Analysis of HDACs in Tumorigenesis.
Hadley M; Noonepalle S; Banik D; Villagra A
Methods Mol Biol; 2019; 1983():279-307. PubMed ID: 31087305
[TBL] [Abstract][Full Text] [Related]
19. HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms.
Manzotti G; Torricelli F; Donati B; Sancisi V; Gugnoni M; Ciarrocchi A
J Exp Clin Cancer Res; 2019 Aug; 38(1):346. PubMed ID: 31395086
[TBL] [Abstract][Full Text] [Related]
20. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]